Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.

@article{Shulak2014HistoneDI,
  title={Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.},
  author={Laura Shulak and Vladimir Beljanski and Cindy Chiang and Sucharita M. Dutta and Julien van Grevenynghe and Sidi Mehdi Belgnaoui and Thi Li{\^e}n-Anh Nguy{\^e}n and Thomas Z. Di Lenardo and O. John Semmes and Rongtuan Lin and John Hiscott},
  journal={Journal of virology},
  year={2014},
  volume={88 5},
  pages={2927-40}
}
Vesicular stomatitis virus (VSV) is an oncolytic virus that induces cancer cell death through activation of the apoptotic pathway. Intrinsic resistance to oncolysis is found in some cell lines and many primary tumors as a consequence of residual innate immunity to VSV. In resistant-tumor models, VSV oncolytic potential can be reversibly stimulated by combination with epigenetic modulators, such as the histone deacetylase inhibitor vorinostat. Based on this reversible effect of vorinostat, we… CONTINUE READING
Highly Cited
This paper has 41 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.

Molecular therapy : the journal of the American Society of Gene Therapy • 2013

Similar Papers

Loading similar papers…